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Abstract
Background:  Targeting tumor angiogenesis and vasculature is a promising strategy for the
inhibition of tumor growth and dissemination. Evidence suggests that tumor vasculature expresses
unique markers that distinguish it from normal vasculature. Our efforts focused on the molecular
characterization of endothelial cells (EC) in the search for selective markers of tumor vasculature
that might be helpful for the development of effective therapeutic approaches.
Results: We investigated by microarray analysis the gene expression profiles of EC purified and
cultured from tumor (ovarian carcinoma [HOC-EC]) and normal (human adrenal gland [HA-EC])
tissue specimens. We found distinct transcriptional features characterizing the EC of different
origin, and identified 158 transcripts highly expressed by HOC-EC. We analyzed four of these
genes, ADAM23, FAP, GPNMB and PRSS3, which were not previously known to be expressed by
endothelium. In vitro experiments confirmed the higher expression of the selected genes in tumor-
derived endothelium with no expression in tumor cells. In vivo investigation by in situ hybridization
established that ADAM23, GPNMB and PRSS3 expression is localized on blood vessels of human
cancer specimens.
Conclusion: These findings elucidate some of the molecular features of the tumor endothelium.
Comparative transcriptomic analysis allowed us to determine molecular differences of tumor and
normal tissue-derived endothelium and to identify novel markers that might be exploited to
selectively target tumor vasculature.
Background
Interference with tumor vessel formation and blood sup-
ply has become a well-recognized approach of cancer
therapy [1], as epitomized by the recent FDA approval of
antiangiogenic drugs such as the humanized anti Vascular
Endothelial Growth Factor (VEGF) antibody Avastin® [2].
Vascularization is required for tumor growth and metasta-
sis, and constitutes an important step in the control of
cancer progression [3]. Experimental evidence correlates
tumor vascularization with high malignancy and poor
prognosis, and shows that elevated levels of angiogenic
factors, such as VEGF and basic Fibroblast Growth Factor
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(FGF-2), are associated with tumor progression [4]. More-
over, expansive growth of metastasis appears to be linked
to the ability to stimulate endothelial cell growth [5].
Tumor-induced vessels are ultrastructurally abnormal and
differ from normal vasculature. They lack functional peri-
cytes and are unusually permeable [6]. These abnormali-
ties reflect the pathological nature of their induction, and
underpin the novel therapeutic strategies directed against
the vascular elements of the tumor stroma to selectively
affect tumor vasculature and inhibit tumor growth [7].
In recent years an increasing body of evidence suggests
that tumor vasculature expresses unique markers that dis-
tinguish it from normal vasculature. Numerous efforts
have been aimed at the molecular characterization of
tumor associated endothelial cells (EC) in the search for
differences between tumor and normal tissue EC. A vari-
ety of techniques have been applied to study EC in vivo,
isolated from ex vivo specimens or cultured in vitro. The in
vivo phage display technology was used to identify mole-
cules selectively expressed on tumor endothelium [8,9],
while other approaches exploited the in vivo proteomic
analysis to detect antigens accessible from the vasculature
[10,11]. These techniques have allowed, mostly through
studies conducted in experimental tumor models, the
identification of vascular-specific motifs expressed by dif-
ferent tumor types and during different stages of carcino-
genesis.
Gene expression of EC isolated from ex vivo human cancer
and normal specimens, analyzed by means of Serial Anal-
ysis of Gene Expression (SAGE) or microarray, revealed
differences at the transcriptional level in tumor and nor-
mal tissues [12-15]. In vitro models have been widely used
to identify the specific functions of the endothelium and
to understand the molecular modifications that might
occur during angiogenesis. In these studies EC were
exposed to different microenvironmental conditions,
such as angiogenic growth factors and matrix proteins,
shear stress, hypoxia, or tumor conditioned media [16-
20]. All of these approaches led to the identification of
mechanisms and molecules that are potentially involved
in the formation of blood vessels. Despite these findings,
attempts to discover tumor EC markers have always been
hampered by technical difficulties in isolating function-
ally intact and phenotypically stable EC from tumor tis-
sues. In fact, all the in vitro models have used cultures of
immortalized EC and/or primary EC from human umbil-
ical vein (HUVEC).
We developed a method to isolate and culture EC from
tumor specimens (TdEC), by which we were able to show
that TdEC in vitro maintain several of the features
described for tumor vasculature and that they differ from
EC isolated from normal tissue (i.e., from human adrenal
gland HA-EC) [21]. These findings suggested that TdEC
and HA-EC might represent useful tools to study tumor
vessel properties and, ultimately, to identify tumor vascu-
lature markers.
Here we describe the isolation of EC from human speci-
mens and the characterization of the transcriptional pro-
files of EC derived from ovarian carcinoma (HOC-EC)
and HA-EC by means of microarray technology. Through
the comparison of HOC-EC and HA-EC gene expression
we were able to demonstrate that tumor-associated EC dif-
fer from those in normal tissues, thus proving that molec-
ular differences are maintained in vitro. We successfully
identified molecules that are expressed selectively by the
tumor vasculature in vivo, thus providing distinctive fea-
tures to be exploited to selectively target tumor vascula-
ture.
Results
Characterization of Endothelial Cells (EC) isolated from 
human specimens
Endothelial cells were reproducibly isolated from human
tissue specimens: HOC-EC from ovarian carcinoma,
HKC-EC from kidney carcinoma, HA-EC from adrenal
gland and HSk-EC from skin.
Before use, their endothelial origin was established.
Endothelial cell cultures typically created a homogeneous
monolayer of elongated cells in close contact and main-
tained an uniform morphology after few passages in cul-
ture; they formed capillary-like cord structures when
plated on matrigel (data not shown and [21]). Their
endothelial origin was established by positive immunos-
taining for platelet-endothelial cell adhesion molecule-1
(CD31/PECAM-1), von Willebrand Factor (vWF) and vas-
cular E-cadherin (VE-cadherin) (Table 1). In addition, no
staining was observed when the cells were analyzed for
the expression of alpha-Smooth Muscle Actin (alpha-
SMA), a typical non-endothelial marker (Table 1). Flow
cytometry studies assessed the ability to uptake low den-
sity lipoproteins (LDL), a characteristic of endothelial
cells, and confirmed the positivity for CD31/PECAM-1
(data not shown).
The purity of the isolated EC was comparable to that of EC
from umbilical vein (HUVEC), which were used as the ref-
erence population for EC (Table 1).
Microarray results, performed on HA-EC and HOC-EC,
confirmed the endothelial origin of the isolated cells
(Table 2). The typical endothelial genes expressed at high
levels include COL8A1, COL18A1, CYR61, endoglin, E-
selectin, HIF1A, ICAM-1, JAM3 junctional adhesion mol-
ecule, neuropilin-2, PAR-1 thrombin receptor, P-selectin,BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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TEK endothelial tyrosine kinase, VEGFR-1, and VEGFR-2.
Among these, the presence of transcripts for CD31/
PECAM-1, VE-cadherin and vWF, whose protein expres-
sion was shown by immunohistochemical methods
(Table 1), is worth emphasizing.
Genome wide transcriptional differences: tumor vs. normal 
tissue derived EC
Comparison of the transcriptional profiles of HOC-EC
and HA-EC (experimental design and analyses detailed in
Methods) showed that EC from tumor and normal tissue
have distinct and characteristic expression patterns that
are maintained in vitro. According to our selection criteria,
158 gene transcripts, corresponding to 179 probe sets,
were more expressed by HOC-EC than by HA-EC. The
genes belong to the different functional classes that are
listed in Table 3.
Microarray results reveal an alteration in cell-cell and cell-
matrix interaction as shown by the enhanced expression
of molecules such as desmoglein 2, N- and OB-cadherin,
protocadherin-9 and -17 and P-selectin (Table 3A). In
keeping with the notion that the extracellular matrix in
tumor differs from that in normal tissue [22] glypican-1,
laminin alpha 3, tenascin C, versican, as well as different
types of collagens (collagen typeI-alpha2, typeIII-alpha1,
typeV-alpha1, typeXIII-alpha1 and typeXV-alpha1) and
thrombospondin-2, were expressed at higher levels by
HOC-EC than by HA-EC (Table 3A). Moreover, altera-
tions of cytoskeletal protein involved in cell motility, for
instance the actin and myosin related molecules MYOM1,
MYL9 and RIPX, were also observed (Table 3A).
The peptidase family is the most represented among the
enzymatic classes of genes expressed by HOC-EC (Table
3B). It includes carboxypeptidase A3, carboxypeptidase E,
cathepsin Z, membrane metallo-endopeptidase, serinpro-
tease 11, and urokinase-plasminogen activator. This is
consistent with the concept that peptidases are very
important for the activation of pro-enzymes or protein
precursors, as well as in the degradation of the extracellu-
lar matrix [23].
Most of the listed genes are involved in signaling and
comprise molecules previously shown to be involved in
angiogenesis and other vascular functions, such as
adrenomedullin receptor, CD44, endothelin-1 and -2,
endothelin receptor-A and tissue factor (Table 3C).
Consistent with the notion that the vascular and nervous
systems share similar signals and principles [24], 3 mem-
bers of the GABA receptors family and several molecules
involved in synaptic signaling, as well as elements
involved in brain differentiation and axon elongation,
were expressed at higher levels by HOC-EC (Table 3C).
Four members of the Solute Carrier Family (SLC1A1,
SLC7A2, SLC16A4, SLC20A2) were over-expressed in
HOC-EC, suggesting an alteration in the extra-intracellu-
lar exchange of metabolites (Table 3C). Among the trans-
porters, the enhanced expression of the ATP-binding
cassette family members ABCA2 and ABCB1 (Table 3B)
should be emphasized. ABCB1, best known as MDR/p-
glycoprotein, is involved in drug removal from cells.
Higher expression also affected genes involved in tran-
scriptional response, such as members of the zinc finger
protein family (DZIP1, JMJD2B, SNAI2, WT1, ZNF212,
ZNF365, ZNF415) and of the homeobox family (HOP,
MEOX2, MSX2, TLX1) (Table 3D).
SMAD7 (Table 3D) and BAMBI (Table 3A), involved and
acting as inhibitors of TGF-beta signaling, were also more
expressed.
Among the class of cell cycle regulators, the high expres-
sion of the anti-apoptotic protein BCL2 is noteworthy
(Table 3E).
Table 1: Typical endothelial signatures of the cells isolated from human cancer and normal tissue specimens
CD31/PECAM-1 vWF* VE-cadherin alpha-SMA
HOC-EC (n = 9) 73–98 75–99 97–100 0
HKC-EC (n = 3) 85–93 27–67 nt 0
HA-EC (n = 9) 94–99 30–90 99–100 0
HSk-EC (n = 2) 95–97 80–99 nt 0
HUVEC (n = 6) 80–99 90–99 99–100 0
Percentages of positive cells analyzed by immunohistochemistry evaluating a total of 500 cells/population. In parentheses are the number of 
independent human EC populations evaluated (HOC-EC = ovarian carcinoma EC; HKC-EC = kidney carcinoma EC; HA-EC = adrenal gland-EC; 
HSk-EC = skin-EC, HUVEC = umbilical vein EC).
Shown are the range of values obtained for the different endothelial cell types.
* Population showing positivity values below 65% were not utilized. nt=not determinedBMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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Selected transcripts are expressed by tumor derived 
endothelial cells
In order to identify novel markers of tumor endothelium
our attention focused on transcripts that are highly
expressed by tumor-derived endothelium (i.e., HOC-EC),
but whose products and functions were not previously
reported as being involved in tumor angiogenesis or asso-
ciated to vascular functions. Among them we distin-
guished four genes on the basis of their structural or
functional characteristics, such as the presence of trans-
membrane domains and/or enzymatic activities: disin-
tegrin and metalloproteinase domain 23 (ADAM23),
fibroblast activation protein alpha (FAP), transmembrane
glycoprotein nmb (GPNMB), and serine protease 3 or
mesotrypsin (PRSS3). The relative expression in HOC-EC
compared to HA-EC was 2.6 for ADAM23, 4.1 for FAP, 4.6
for GPNMB and 2.5 for PRSS3, as calculated from micro-
array data. These results were validated by real-time PCR
in EC isolated from six neoplastic tissues (five ovarian and
one kidney carcinoma specimens) and from four non-
neoplastic tissues (three adrenal glands and one skin spec-
imen) different from those investigated by microarray.
These tumor or normal tissue derived EC are described in
Table 1.
Table 2: Typical endothelial genes highly expressed by HOC-EC and HA-EC
Unigene Cluster Symbol Gene Name
Hs.83347 AAMP Angio-associated, migratory cell protein
Hs.426312 AMOTL2 Angiomotin like 2
Hs.521731 ANGPTL2 Angiopoietin-like 2
Hs.448589 ANKRD1 Ankyrin repeat domain 1 (cardiac muscle)
Hs.185055 BENE BENE protein
Hs.495731 BMX BMX non-receptor tyrosine kinase
Hs.76206 CDH5 Cadherin 5, type 2, VE-cadherin (vascular epithelium)
Hs.482562 F2R Coagulation factor II (thrombin) receptor, PAR-1
Hs.134830 COL8A1 Collagen, type VIII, alpha 1
Hs.517356 COL18A1 Collagen, type XVIII, alpha 1
Hs.410037 CTGF Connective tissue growth factor
Hs.8867 CYR61 Cysteine-rich, angiogenicinducer, 61
Hs.174050 EDF1 Endothelial differentiation-related factor 1
Hs.76753 ENG Endoglin (Osler-Rendu-Weber syndrome 1)
Hs.129944 ESM1 Endothelial cell-specific molecule 1
Hs.154210 EDG1 Endothelial differentiation, sphingolipid G-protein-coupled receptor, 1
Hs.122575 EDG4 Endothelial differentiation, lysophosphatidicacid G-protein-coupled receptor, 4
Hs.468410 EPAS1 Endothelial PAS domain protein 1
Hs.507621 FLT-1 Fms-related tyrosine kinase 1
Hs.367725 GATA2 GATA binding protein 2
Hs.201712 GLG1 Golgi apparatus protein 1
Hs.509554 HIF1A Hypoxia-inducible factor 1, alpha subunit
Hs.515126 ICAM-1 Intercellular adhesion molecule 1 (CD54)
Hs.150718 JAM3 Junctional adhesion molecule 3
Hs.479756 KDR Kinase insert domain receptor
Hs.268107 MMRN1 Multimerin 1
Hs.471200 NRP2 Neuropilin 2
Hs.511603 NOS3 Nitric oxide synthase3
Hs.514412 PECAM1 Platelet/endothelial cell adhesion molecule (CD31 antigen)
Hs.405156 PPAP2B Phosphatidic acid phosphatase type 2B
Hs.252820 PGF Placental growth factor, vascular endothelial growth factor-related protein
Hs.82353 PROCR Protein C receptor, endothelial (EPCR)
Hs.89546 SELE Selectin E (endothelial adhesion molecule 1)
Hs.73800 SELP Selectin P (granule membrane protein 140kDa, antigen CD62)
Hs.514913 SERPINB2 Serine (or cysteine) proteinaseinhibitor, clade B (ovalbumin), member 2
Hs.414795 SERPINE1 Serine (or cysteine) proteinaseinhibitor, clade E, member 1
Hs.89640 TEK TEK tyrosine kinase, endothelial
Hs.50382 TJP2 Tight junction protein 2 (zona occludens 2)
Hs.76090 TNFAIP1 Tumor necrosis factor, alpha-induced protein 1(endothelial)
Hs.525607 TNFAIP2 Tumor necrosis factor, alpha-induced protein 2
Hs.440848 VWF Von Willebrand factor
Three HOC-EC and two HA-EC populations were investigated by Affymetrix GeneChip® Human Genome U95A Arrays. This list of highly 
expressed endothelial genes was extracted from the microarray results by keywords search within the complete probeset list annotated using 
SOURCE batch search (see Methods for details).BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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Table 3: Transcriptional differences: tumor vs normal tissue derived EC
Unigene Cluster Symbol Gene Name
Structural A
Hs.370287 ADAM23 A disintegrin and metalloproteinase domain 23
Hs.118127 ACTC Actin, alpha, cardiac muscle
Hs.533336 BAMBI BMP and activin membrane-bound inhibitor homolog
Hs.489142 COL1A2 Collagen, type I, alpha 2
Hs.443625 COL3A1 Collagen, type III, alpha 1
Hs.210283 COL5A1 Collagen, type V, alpha 1
Hs.211933 COL13A1 Collagen, type XIII, alpha 1
Hs.409034 COL15A1 Collagen, type XV, alpha 1
Hs.80552 DPT Dermatopontin
Hs.412597 DSG2 Desmoglein 2
Hs.159291 DRP2 Dystrophin related protein 2
Hs.371903 GYPE Glycophorin E
Hs.190495 GPNMB Glycoprotein (transmembrane) nmb
Hs.328232 GPC1 Glypican 1
Hs.435557 KIF5C Kinesin family member 5C
Hs.436367 LAMA3 Laminin, alpha 3
Hs.519972 HLA-F Major histocompatibility complex, class I, F
Hs.490874 MTX1 Metaxin 1
Hs.464469 MYOM1 Myomesin 1 (skelemin)
Hs.504687 MYL9 Myosin, light polypeptide 9, regulatory
Hs.464829 CDH2 N-cadherin
Hs.116471 CDH11 OB-cadherin
Hs.487925 PDE4DIP Phosphodiesterase 4D interacting protein (myomegalin)
Hs.157818 KCNAB1 Potassium voltage-gated channel, shaker-related subfamily, beta member 1
Hs.407643 PCDH9 Protocadherin 9
Hs.106511 PCDH17 Hypothetical protein LOC144997
Hs.7972 RIPX Rap2 interacting protein x
Hs.73800 SELP Selectin P
Hs.468675 T1A-2 T1A-2 (lung type-I cell membrane-associated glycoprotein)
Hs.143250 TNC Tenascin C
Hs.371147 THBS2 Thrombospondin 2
Hs.443681 CSPG2 Versican
Hs.529901 XIST X (inactive)-specific transcript
Enzymatic B
Hs.459538 ALDH1A3 Aldehyde dehydrogenase 1 family, member A3
Hs.421202 ABCA2 ATP-binding cassette, sub-family A (ABC1), member 2
Hs.489033 ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1
Hs.646 CPA3 Carboxypeptidase A3
Hs.75360 CPE Carboxypeptidase E
Hs.252549 CTSZ Cathepsin Z
Hs.154654 CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1
Hs.516493 FAP Fibroblast activation protein, alpha
Hs.30332 GFPT2 Glutamine-fructose-6-phosphate transaminase 2
Hs.301961 GSTM1 Glutathione S-transferase M1
Hs.470126 KYNU Kynureninase (L-kynurenine hydrolase)
Hs.65436 LOXL1 Lysyl oxidase-like 1
Hs.307734 MME Membrane metallo-endopeptidase
Hs.478289 NLGN1 Neuroligin 1
Hs.30954 PMVK Phosphomevalonate kinase
Hs.77274 PLAU Plasminogen activator, urokinase
Hs.446429 PTGDS Prostaglandin D2 synthase 21 kDa
Hs.501280 PRSS11 Protease, serine, 11 (IGF binding)
Hs.303090 PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C
Hs.128013 PRSS3 Protease, serine, 3
Hs.270279 TYRP1 Tyrosinase-related protein 1
Hs.13225 B4GALT4 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4
Hs.69009 B3GNT3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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Signaling C
Hs.143102 AB012943 Amine oxidase, copper containing 2
Hs.167046 ADORA2B Adenosine A2b receptor
Hs.483909 ADMR Adrenomedullin receptor
Hs.132902 CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast)
Hs.502328 CD44 CD44 antigen
Hs.78065 C7 Complement component 7
Hs.473133 DOK5 Docking protein 5
Hs.523173 ENTPD1 Ectonucleoside triphosphate diphosphohydrolase 1
Hs.511899 EDN1 Endothelin 1
Hs.1407 EDN2 Endothelin 2
Hs.183713 EDNRA Endothelin receptor type A
Hs.481371 FAT FAT tumor suppressor homolog 1 (Drosophila)
Hs.352 FOLR3 Folate receptor 3 (gamma)
Hs.432395 GPR39 G protein-coupled receptor 39
Hs.79022 GEM GTP binding protein overexpressed in skeletal muscle
Hs.198612 GPR51 G protein-coupled receptor 51
Hs.156855 GABRG3 Gamma-aminobutyric acid (GABA) A receptor, gamma 3
Hs.167017 GABBR1 Gamma-aminobutyric acid (GABA) B receptor, 1
Hs.98262 GRIK2 Glutamate receptor, ionotropic, kainate 2
Hs.124161 HCN2 Hyperpolarization activated cyclic nucleotide-gated potassium channel 2
Hs.370984 IGSF4C Immunoglobulin superfamily, member 4C
Hs.438102 IGFBP2 Insulin-like growth factor binding protein 2
Hs.369982 IGFBP5 Insulin-like growth factor binding protein 5
Hs.81134 IL1RN Interleukin 1 receptor antagonist
Hs.126256 IL1B Interleukin 1, beta
Hs.129751 IL17R Interleukin 17 receptor
Hs.514535 LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein
Hs.125474 LPXN Leupaxin
Hs.36566 LIMK1 LIM domain kinase 1
Hs.304475 LCP2 Lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76 kDa)
Hs.418367 NMU Neuromedin U
Hs.514556 NPTX1 Neuronal pentraxin I
Hs.8546 NOTCH3 Notch homolog 3 (Drosophila)
Hs.434255 PSD3 Pleckstrin and Sec7 domain containing 3
Hs.506076 PTPRR Protein tyrosine phosphatase, receptor type, R
Hs.436456 ROR1 Receptor tyrosine kinase-like orphan receptor 1
Hs.24950 RGS5 Regulator of G-protein signalling 5
Hs.194691 RAI3 Retinoic acid induced 3
Hs.95655 SECTM1 Secreted and transmembrane 1
Hs.516726 SCG2 Secretogranin II (chromogranin C)
Hs.156540 SGNE1 Secretory granule, neuroendocrine protein 1 (7B2 protein)
Hs.75149 SH3GL2 SH3-domain GRB2-like 2
Hs.444915 SLC1A1 Solute carrier family 1, member 1
Hs.448520 SLC7A2 Solute carrier family 7, member 2
Hs.351306 SLC16A4 Solute carrier family 16, member 4
Hs.192686 SLC20A2 Solute carrier family 20, member 2
Hs.12409 SST Somatostatin
Hs.62886 SPARCL1 SPARC-like 1 (mast9, hevin)
Hs.233160 STC2 Stanniocalcin 2
Hs.258326 LOC51760 Synaptotagmin 1
Hs.349470 SNCG Synuclein, gamma
Hs.62192 TF Tissue factor
Hs.534363 UCN Urocortin
Hs.73793 VEGF Vascular endothelial growth factor
Hs.306251 ERBB3 V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
Transcriptional factors and regulators D
Hs.65734 ARNTL Aryl hydrocarbon receptor nuclear translocator-like
Hs.397705 CAMTA1 Calmodulin binding transcription activator 1
Hs.157002 DZIP1 DAZ interacting protein 1
Table 3: Transcriptional differences: tumor vs normal tissue derived EC (Continued)BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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Hs.22634 ETV1 ets variant gene 1
Hs.155591 FOXF1 Forkhead box F1
Hs.519385 FOXD1 Forkhead related activator 4 (FREAC-4)
Hs.121443 HOP Homeodomain-only protein
Hs.180919 ID2 Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
Hs.371013 JMJD2B Jumonji domain containing 2B
Hs.434284 LRRC17 Leucine rich repeat containing 17
Hs.527007 MEOX2 Mesenchyme homeo box 2 (growth arrest-specific homeo box)
Hs.89404 MSX2 Msh homeo box homolog 2 (Drosophila)
Hs.1497 RARG Retinoic acid receptor, gamma
Hs.149261 RUNX1 Runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene)
Hs.465087 SMAD7 SMAD, mothers against DPP homolog 7 (Drosophila)
Hs.360174 SNAI2 Snail homolog 2 (Drosophila)
Hs.89583 TLX1 T-cell leukemia, homeobox 1
Hs.149991 THOC2 THO complex 2
Hs.125962 TFEC Transcription factor EC
Hs.1145 WT1 Wilms tumor 1
Hs.490510 ZNF212 Zinc finger protein 212
Hs.22653 ZNF365 Zinc finger protein 365
Hs.147765 ZNF415 Zinc finger protein 415
DNA replication, Cell Cycle and Apoptosis E
Hs.75823 AF1Q ALL1-fused gene from chromosome 1q
Hs.150749 BCL2 B-cell CLL/lymphoma 2
Hs.122908 CDT1 DNA replication factor
Hs.9999 EMP3 Epithelial membrane protein 3
Hs.52903 8FSTL3 Follistatin-like 3 (secreted glycoprotein)
Hs.130853 HIST1H2BD Histone 1, H2bd
Hs.534369 HIST1H2BE Histone 1, H2be
Hs.152944 LOH11CR2A Loss of heterozygosity, 11, chromosomal region 2, gene A
Hs.432132 G0S2 Putative lymphocyte G0/G1 switch gene
Hs.514913 SERPINB2 Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2
Others and unknown F
Hs.441783 C14orf78 C14orf78
Hs.516956 C20orf91 chromosome 20 open reading frame 91 Hs.17936
DKFZP434H132 DKFZP434H132 protein
Hs.132994 DKFZP434C171 DKFZP434C171 protein
Hs.41707 HSPB3 Heat shock 27 kDa protein 3
Hs.432616 IMP-3 IGF-II mRNA-binding protein 3
Hs.534372 INE1 Inactivation escape 1
Hs.464563 KIAA0802 KIAA0802
Hs.65750 KIAA1086 KIAA1086
Hs.472010 PRNP Prion protein (p27-30)
AC006276
U62317
W26626
W28546
List of the 158 gene transcipts more expressed by HOC-EC than HA-EC.
Three HOC-EC and two HA-EC populations were investigated by Affymetrix GeneChip® Human Genome U95A Arrays and analyzed searchingfor 
intrinsic differences, as described in Methods.
Table 3: Transcriptional differences: tumor vs normal tissue derived EC (Continued)BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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To mimic the different environments in which EC might
be embedded in vivo – either subjected to persistent stim-
ulation imposed by the tumor cells or not, EC were inves-
tigated both in the presence (Figure 1A) or the absence
(Figure 1B) of the angiogenic factors VEGF, FGF- 2, of epi-
dermal growth factor (EGF) and of fibronectin. Under
both conditions the expression of ADAM23, FAP, GPNMB
and PRSS3 genes was much higher in EC isolated from
tumor specimens, as shown by the fold difference values
(Figures 1A and 1B). As specified by the p values, statisti-
cal analysis demonstrated a significant disparity in the
expression levels for each of the genes being investigated
(Figures 1A and 1B).
These results confirm microarray findings and demon-
strate that such a diversity is indeed an intrinsic character-
istic associated to the tumor or normal tissue origin of the
EC, regardless of the culture conditions. Sarcoglycan epsi-
lon (SCGE), chosen as an internal control of a gene
expressed to a much lesser extent by HOC-EC, confirmed
the microarray results (Figures 1A and 1B).
Expression in non endothelial cells
Having shown that ADAM23, FAP, GPNMB, and PRSS3
were expressed by a panel of EC, with the highest expres-
sion found in TdEC, we next investigated their expression
in other cell types. The gene expression analysis revealed
that they could be expressed to different extents also by
other stromal cells, such as fibroblasts (HuFb and
Malme3) and smooth muscle cells (UASMC), but in gen-
eral not by tumor cells (Figure 2). Specifically, their
expression in the carcinoma cell lines (1A9 and SKOV3
ovarian, MDA-MB-431 breast and HT29 colon) was not or
was barely detectable (with the exception of PRSS3 by the
HT29 colon carcinoma) (Figure 2). This lack of expression
was supported by the Northern Blot results of a panel of
tumor cell lines represented on the Multiple Tissue
Expression array (Figure 3). Moreover, the Reference data-
base for gene Expression Analysis (RefExA [25]) con-
firmed that the tumor cell lines did not show expression
of the selected genes.
Conversely, the expression of FAP and GPNMB was higher
in both the HuFb and MALME 3 fibroblasts than in EC,
and FAP was also expressed at a higher level by the
UASMC smooth muscle cells. ADAM23 and PRSS3 were
instead expressed to a lesser extent by all the stromal cells
analyzed (Figure 2).
Expression in healthy tissues
Tissue expression of ADAM23 and GPNMB was assessed
using a Multiple Tissue Expression (MTE) array: a panel of
human mRNAs in dot-blot format from 58 normal adult
tissues, seven fetal tissues, and eight cell lines. As shown
in Figure 3, ADAM23 and GPNMB were expressed by a
limited subset of tissues, while tumor cells did not express
either one of them. In particular, ADAM23 expression was
highest in cardiovascular tissues and fetal heart, as well as
in central nervous system (CNS) samples, while it was
much lower in fetal brain (Figure 3). The expression of
GPNMB was highest in cardiovascular tissues and fetal
heart, as well as in placenta, while it was detected to a
much lesser extent in lung, uterus, and bladder tissue.
(Figure 3). These Northern Blot results for ADAM23 and
GPNMB expression were confirmed by the RefExA data-
base [25].
Real-time PCR quantification of gene expression in endothe- lial cells isolated from human cancer and normal tissue speci- mens Figure 1
Real-time PCR quantification of gene expression in 
endothelial cells isolated from human cancer and 
normal tissue specimens. Endothelial cells were exposed 
(A) or not (B) to VEGF, EGF, FGF-2 and fibronectin (see 
Methods for details). Fold differences for each EC population 
and p values for each gene analyzed are shown. The expres-
sion of the target gene was normalized to 18s rRNA for each 
of the EC populations being evaluated: ΔCt = Cttarget - Ct18s. 
Statistical analysis on ΔCt values was performed comparing 
tumor and normal tissue derived EC. Fold differences were 
calculated according to the comparative ΔΔCt method: Fold 
difference = 2 -(ΔCt each population-ΔCt ref) by arbitrarily consider-
ing the normal tissue derived ECs as reference (ΔCtref being 
their average ΔCt value).
10
e
A P=0.0009 P=0.0499 P=0.0045 P<0.0001 P=0.0558
1
F
o
l
d
 
d
i
f
f
e
r
e
n
c
e
0.1
B P=0.0025 P=0.011 P=0.0044 P=0.0462 P=0.0049
10
e
r
e
n
c
e
0.1
1
F
o
l
d
 
d
i
f
f
e
Tumor derived EC Normal tissue derived EC Median
0.1
ADAM23 GPNMB PRSS3 FAP SGCEBMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
Page 9 of 18
(page number not for citation purposes)
Data from RefExA [25] and literature report the expression
of PRSS3 by brain, colon and pancreas [26], while FAP
expression is described only in the activated stromal
fibroblast of tumors [27].
Expression by tumor vasculature in vivo
In order to investigate the in vivo localization of ADAM23,
GPNMB and PRSS3, human tumor tissues were analyzed
by in situ hybridization.
Endothelial expression of the selected genes was con-
firmed in the tumor samples analyzed. As shown in Figure
4, the hybridization signals for ADAM23, GPNMB, and
PRSS3 localized around the blood vessels, and exclusively
in the vascular walls. According to the in vitro results,
tumor cells did not express the transcripts, as shown by
the absence of staining in the parenchyma of the tissues
(Figure 4A, B, C). Noteworthy was the finding that stro-
mal compartments (except for the blood vessels) lacked
the expression of either gene.
No staining was observed in normal brain and Alzhe-
imer's-diseased brain (Figures 4G, H, I). It is remarkable
that ADAM23 and PRSS3 transcripts, whose expression in
CNS was revealed by the MTE array and/or reported by
RefExA [25], were not detected in normal or diseased
brain, except for blood vessels in medulloblastoma or
metastatic adenocarcinoma (Figure 4 and data not
shown).
Sense probes did not hybridize with any of the tissue sec-
tions analyzed (Figures 4D, E, F).
Discussion
Targeting the process of tumor neovascularization has
become a promising anti-cancer strategy. This is particu-
larly evident when vascular targeting agents are combined
with conventional chemotherapy and radiotherapy, as
demonstrated by recent reports and clinical trials [28].
However, the success of this approach depends on the
availability of suitable endothelial markers that can be
used to selectively target the tumor vascular compartment
or to deliver a ligand-directed effector to the endothelium
[7]. Herein, we successfully combined a method to isolate
and culture endothelial cells (EC) from human specimens
of tumor (TdEC) and non-neoplastic (NdEC) origin with
oligonucleotide microarray analysis to compare their gene
expression. We first showed that the TdEC transcriptional
profile differs from that of NdEC, and, thereafter identi-
fied specific molecular features of tumor-derived endothe-
lium.
Our laboratory previously established a procedure [29] to
derive EC of high purity from human specimens, their ori-
gin assessed by immunohistochemical staining for the
Gene expression in different cell lines Figure 2
Gene expression in different cell lines. Levels of expres-
sion of ADAM23, FAP, GPNMB and PRSS3 were evaluated in 
fibroblasts (HuFb and Malme3) and smooth muscle cells 
(USMAC) as well as in tumor cell lines (1A9, SKOV3, HT29 
and MDA-MB-231). Gene expression of each target gene was 
normalized to 18s rRNA for each cell type (ΔCt = Cttarget - 
Ct18s). Average of ΔCt of the target gene from tumor 
derived ECs (Figure 1) was assumed as reference (ΔCtref). 
Fold differences for each cell type were calculated according 
to the comparative ΔΔCt method (Fold difference = 2-(ΔCt 
each celltype-ΔCt ref)) and expressed as percentage relative to 
tumor-derived EC (100%).
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Tissue expression of ADAM23 and GPNMB Figure 3
Tissue expression of ADAM23 and GPNMB. ADAM23 and GPNMB expression were evaluated by Multiple Tissue 
Expression array. The membrane, comprising polyA+ mRNA from different adult and fetal tissues, was hybridized with a 32P 
labeled probe specific for the two genes and hybridization visualized by autoradiography. Bars represent the optical density 
evaluated for each dot.
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three endothelial markers CD31/PECAM-1, VE-cadherin
and vWF. Accordingly, microarray results confirmed their
expression, but also revealed the expression of many other
genes annotated as typically endothelial through
SOURCE [30]. These included E-selectin, VEGFR-1, and
VEGFR-2, further confirming our previous findings [21].
Despite being less successful with tumors (e.g., a 50% suc-
cess rate out of 18 ovarian carcinoma specimens) than
with non neoplastic (a 90% success rate for adrenal
gland), the reproducible yield of EC from human speci-
mens enabled us to explore molecular differences
between tumor and normal endothelium.
The comparative transcriptomic analysis of EC from ovar-
ian carcinoma (HOC-EC) and adrenal gland (HA-EC)
revealed the higher expression of 158 gene transcripts by
HOC-EC. The finding that tumor and normal tissue EC
have distinct gene expression patterns concurs with other
investigations, which describe genes that are preferentially
expressed by endothelium from malignant cancer [12-
15]. In these studies, SAGE [12-14] or microarray analyses
[15] were executed on EC freshly obtained by immunose-
lection of ex vivo tissue samples. Endothelial cells in cul-
ture often lose their tissue-specificity and their specialized
properties [31]. Our results, nonetheless, demonstrate
that we were able to preserve in vitro some of the pheno-
types that distinguish the diverse endothelia. Likewise,
they confirm our previous findings [21] and agree with
other reports [32,33] showing that, despite being in cul-
ture, EC isolated from different vascular beds possess
characteristic gene expression profiles.
Here we describe for the first time a much higher expres-
sion of ADAM23, FAP, GNPNB and PRSS3 in EC derived
In situ hybridization of human tissues Figure 4
In situ hybridization of human tissues. Shown are representative samples of medulloblastoma (A), brain metastasis of an 
adenocarcinoma (B) and Ewing sarcoma (C), hybridized with antisense probes for ADAM23, GPNMB and PRSS3, respectively. 
Positively stained blood vessels are indicated by arrows. Related hybridization with control sense probes for ADAM23, 
GPNMB and PRSS3 is shown in panel D-E-F. Normal brain samples, from different donors, hybridized respectively with anti-
sense probes for ADAM23 (G) and GPNMB (H) are shown. Alzheimer's-diseased brain hybridized with antisense probe for 
PRSS3 is shown (I).BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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from six tumor samples than in EC from four normal tis-
sue specimens examined by real-time PCR, whose origin
differed from that investigated by microarray analysis. The
differences we detected between TdEC and NdEC were
maintained whether or not they were exposed to a combi-
nation of pro-angiogenic factors that presumably mimic
the different environmental conditions under which EC
might be embedded in vivo (that is, subjected or not to
persistent stimulation imposed by the tumor cells, as in
the case of blood vessels in adult normal tissues). These
results suggest that the transcriptional differences are not
culture condition artifacts, but, rather, true differences
that distinguish EC of different origin (i.e., tumor vs. nor-
mal).
Despite having mainly utilized EC from ovarian cancer
and from adrenal glands as the non-neoplastic counter-
part, the results hold true for EC isolated from kidney can-
cer and skin specimens (even though only one EC
population could be analyzed). These observations,
would seem to indicate that the EC characteristics we
observed are not organ-specific, but, rather, exclusive of
TdEC. This is in agreement with a recent report [15] that
compared EC freshly isolated from ovarian cancer and
normal ovary in which several of the genes identified as
distinctive of the tumor associated vasculature showed
conserved expression across the EC from other tumor
types, such as colon [12], brain [13] and breast [14].
Cultures of EC are valuable tools for biochemical and
functional analysis, but they do not reflect the physiolog-
ical situation entirely. All the information should be con-
sidered critically from the standpoint of what might occur
in blood vessels in vivo. To this end, in situ hybridization
results confirmed ADAM23, GNPNB and PRSS3 expres-
sion associated to blood vessels in tumor tissues, but the
lack of their expression in cancer cells (as well as in nor-
mal tissue).
Overall, these findings support the premise that endothe-
lial markers identified in vitro are likely to have in vivo rel-
evance, and bear out the validity of our experimental
setting designed to reproduce situations that might occur
in vivo.
ADAM23 belongs to the cellular disintegrins, a family of
membrane-anchored proteins that are potential regula-
tors of cell-to-cell and cell-to-matrix interactions [34] and
for which a specific binding interaction with alphaVbeta3
integrin has been demonstrated [35]. Our MTE array
results showed that ADAM23 is expressed in fetal and
adult heart, and also confirmed its previously reported
expression by fetal and adult brain [34,35]. However, our
in situ hybridization finding (lack of gene expression in
normal or Alzheimer's-diseased brain) contradicted the
latter, which implies that the expression of ADAM23
might indeed be much higher in tumor EC, including
blood vessels in medulloblastoma, a highly malignant
brain tumor, than in the brain. Further studies, aimed to
produce antibodies to ADAM23, are necessary to prove its
suitability as a tumor vascular target. Our results also
revealed that ADAM23 was not expressed in cancer cells.
This observation is consistent with the data available from
RefExA and other recent reports [36], which describe
hypermethylation of the ADAM23 promoter that silences
its expression in breast and pancreatic cell lines and in the
corresponding primary tumors. Our evidence of a high
expression of ADAM23 by TdEC suggests that this protein
might be important for establishing contacts and promot-
ing adhesive functions during the pathological processes
leading to the formation of new blood vessels within the
tumor. In addition, it is intriguing to speculate that this
protein – through its ability to bind alphaVbeta3 – could
play some specialized role in the maintenance of vascular
functions within the tumor. In keeping with this hypoth-
esis is the fact that alphaVbeta3 is expressed by EC and has
been shown to be involved in tumor neo-vascularization
[37].
GPNMB is a type I membrane protein identical to the
hematopoietic growth factor inducible neurokinin-1 type
(HGFIN) [38] sharing similarities with neurokinin-1
(NK1), a receptor for tachykinins and a member of seven
transmembrane G protein coupled receptors. HGFIN was
shown to interact with Substance P (SP), which has been
reported to induce EC proliferation and increase vascular
density in an in vivo model of inflammation, and these
effects could be inhibited by an NK1 receptor antagonist
[39]. The action of SP via the NK1 receptor may be a direct
effect, since NK1 receptors have previously been localized
to endothelium [40], and both SP and selective NK1 ago-
nists were shown to enhance in vitro EC proliferation [41].
Substance P in vivo also contributes to vascular permeabil-
ity, plasma extravasation, and edema [42], all features that
characterize the abnormal vasculature of tumors. Our evi-
dence of a high expression of GPNMB by TdEC suggests
that GPNMB may be a tumor stroma receptor for SP,
involved in tumor angiogenic events and in determining
the distinctive features of tumor vasculature. Corroborat-
ing this premise are data suggesting that, in addition to
NK1 receptors, other mechanisms contribute in mediat-
ing in vivo SP effects on EC [39].
The PRSS3 gene encodes for a trypsinogen whose func-
tions have not yet been fully elucidated [43]. PRSS3 tran-
script, whose expression in CNS is reported by RefExA,
was not detected in normal or Alzheimer's-diseased brain,
except for blood vessels in a brain metastasis. This finding
might mean that the expression of PRSS3 is indeed char-
acteristic of tumor EC, as seen for ADAM23. Our search inBMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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the RefExA and SOURCE databases revealed that PRSS3
was not expressed by tumor cells, with the exception of
colon carcinoma. It seems very plausible that PRSS3 pro-
duced by TdEC may contribute to tumor angiogenesis,
invasion and metastasis through its peptidase activity.
This notion upholds evidence that the migration and
invasion of EC in the tumor tissue requires the activation
of pro-enzymes (such as pro-metalloproteinases) and
protein precursors [44]. To this end, it is noteworthy that
other peptidases (including urokinase-plasminogen acti-
vator [uPA] and FAP) were among the genes we found to
be highly expressed by tumor-derived endothelium. In
particular, uPA is capable of initiating the process of extra-
cellular matrix degradation through the activation of plas-
minogen and matrix metalloproteases; in addition, it has
been shown to be required for the migration of EC during
the process of angiogenesis [45]. It is interesting that the
expression of the uPA receptor (uPAR) was also seen to be
higher in HOC-EC than in HA-EC (C. Ghilardi unpub-
lished observation), a finding that would implicate the
uPA-uPAR system in tumor driven angiogenesis.
Our results show that the cell surface protease FAP was
also expressed at significantly higher levels by TdEC than
by normal EC. FAP was originally reported to be an anti-
gen recognized by F19 antibody in cultured fibroblasts
[27]. Accordingly, its expression in our tests was found to
be much higher in cultured fibroblasts (HuFb and
MALME3) and in smooth muscle cells (UASMC). None-
theless, while normal adult tissues are generally FAP-neg-
ative, its expression is detectable in the stroma of over
90% of carcinomas [27]. Such behavior suggested its suit-
ability for stromal targeting and/or cancer detection and
therapy, and in recent years has underpinned the develop-
ment of a humanized anti-FAP antibody (sibrotuzumab)
and the implementation of clinical trials [46]. Our results
uphold the notion that FAP is a valid target for therapy, be
it as stromal or as vascular marker. In keeping with our
results, the in vivo expression of FAP on blood vessels was
recently demonstrated by Ghersi et al. in invasive breast
ductal carcinoma [47].
Many of the transcripts we found to be expressed at a high
level by EC from neoplastic tissues were previously
reported as being involved in tumor angiogenesis or
expressed by tumor EC. In this regard, it is worth listing
the various types of matrix proteins that we detected,
namely: collagens alpha-2 type I, alpha-1 type III, V, XIII
and XV, glypican-1, laminin alpha3, and tenascin C. Our
results confirm similar findings from other laboratories
[12,13,15] and denote a remodeling of the extracellular
matrix known to promote blood vessel sprouting and
growth. In keeping with the experimental data, and as an
example, tenascin C was shown to be expressed in vivo and
to colocalize with microvessels in the stroma of non-small
cell lung cancer [48].
The expression of cell adhesion proteins was also altered
in TdEC. This may be explained by the fact that migrating
and proliferating EC must "loosen up", that is, detach and
then create new interactions. Our results implicate CD44
and cadherins in this process, and confirm previous
reports showing N-cadherin over-expression on prolifera-
tive state EC [49], and enhanced expression of CD44 on
the vasculature of solid tumors compared to normal tissue
[50]. Noteworthy is the finding that CD44 expression was
up-regulated when the TdEC were exposed to angiogenic
growth factors (C. Ghilardi unpublished observations), in
accordance with previous results showing that FGF-2 and
VEGF stimulate CD44 expression in EC [50].
Interestingly, ABCA2 and ABCB1 (MDR-1/p-glycoprotein
1) were also more abundantly expressed by TdEC, reflect-
ing the previously reported higher expression of p-glyco-
protein 1 in EC from glioma than from normal brain [51].
The ATP-binding cassette transporters (ABC) are responsi-
ble for the efflux of chemotherapeutic agents in cancer
cells [52]. These data suggest that the multidrug resistance
phenomenon in tumors may be due to both EC and
tumor cells.
Molecules such as SMAD7, BAMBI and BCL2 are listed
among the transcripts that are more highly expressed by
HOC-EC than by HA-EC. SMAD7 and BAMBI interfere
with the TGFβ pathway and may potentially block the
anti-proliferative action of TGFβ [53]. Their expression
may induce an enhanced proliferation of the TdEC, which
is one of the steps of the angiogenic process. BCL2 is one
of the most widely recognized anti-apoptotic factors,
whose upregulation enhances EC survival and intratu-
moral angiogenesis, thus promoting tumor growth [54].
Emerging studies suggest that the vascular and the nerv-
ous systems share the same molecular signals in their
development. The involvement of netrins, semaphorins,
Robo/Slit and VEGF families in both angiogenesis and
neurogenesis has been demonstrated in recent years [24].
In keeping with these findings, our results revealed that
TdEC express numerous molecules that are associated
with the CNS or are implicated in brain differentiation
and axon guidance. In particular, ADORA2B was identi-
fied as a novel netrin-1 receptor and reported to mediate
axon outgrowth [55]. In a similar way – and considering
that netrin-1 is pro-angiogenic [56] – our results allow
speculatation that ADORA2B could mediate the sprouting
of vessels during tumor neovascularization.BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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Conclusion
Targeting angiogenesis and vasculature represents a prom-
ising option to control tumor growth and dissemination.
To exploit this opportunity, however, selective targets in
tumor associated vasculature need to be identified.
We describe a model consisting of in vitro cultured
endothelial cells isolated from human normal and neo-
plastic specimens that maintained their respective molec-
ular phenotype and enabled us to determine molecular
differences between tumor and normal tissue derived EC.
Specifically, we identified four transcripts whose expres-
sion is much higher in endothelial cells from tumors than
from normal tissue. The in vivo expression in cancer-asso-
ciated blood vessels was confirmed by in situ hybridiza-
tion of human specimens.
This work evinces some of the distinctive features of
tumor-derived endothelium, and identifies potential
markers that may provide the groundwork for novel ther-
apeutic strategies. Future studies are needed to clarify the
functions and roles of these molecules in tumor progres-
sion and vascularization.
Methods
Isolation, culture and characterization of endothelial cells 
(EC)
The method for isolation of EC has been described in
detail by [29,21]. Briefly, tissue specimens were digested
by type I collagenase (EC 3.4.24.3 – clostridiopeptidase A,
Sigma-Aldrich, St. Louis MO, USA – Milan, Italy) and the
suspension plated. Six to 10 days later, the EC were posi-
tively purified using anti-CD31 antibody-coated magnetic
beads, seeded and cultured as detailed in the supplemen-
tary information [see Additional file 1].
Human umbilical vein EC (HUVEC) were obtained fol-
lowing the procedure described by Jaffe [57] and cultured
as detailed in [58].
To confirm their endothelial origin, EC cultures were ana-
lyzed by immunohistochemical methods to evaluate the
expression of von Willebrand Factor (vWF), platelet-
endothelial cell adhesion molecule-1 (CD31/PECAM-1),
Vascular E-cadherin (VE-cadherin), and alpha-smooth
muscle Actin (alpha-SMA), and by fluorescence activated
cell sorter (FACS) to evaluate low-density lipoprotein
(LDL) uptake and CD31/PECAM-1 antigen expression, as
previously described [21].
Cell cultures
HT29 colon carcinoma cells (ATCC-American Type Cul-
ture Collection) were grown in minimum essential
medium (MEM) supplemented with 10% Fetal Bovine
Serum (FBS).
1A9 (a subclone of the A2780 cell line [59]) and SKOV3
human ovarian carcinoma cells, MDA-MB-231 human
breast carcinoma cells, and HuFb and Malme-3 human
fibroblasts (all from ATCC) were grown in RPMI-1640
medium plus 10% FBS.
Umbilical artery smooth muscle cells (UASMC) were pur-
chased from Clonetics (Clonetics-BioWhittaker, Walkers-
ville MD, USA – Caravaggio BG, Italy) and cultured
following the manufacturer's protocol in SmBM Growth
Medium.
RNA isolation
Total RNA was isolated from cultured cells using Trizol®
(GIBCO-Invitrogen) or RNeasy Mini Kit (Qiagen, Mary-
land, USA) following the manufacturer's protocols.
Potential genomic DNA contaminations were removed by
DNAse (Ambion, Austin, USA) treatment followed by
RNA CleanUp with RNeasy Mini Kit. The purity and integ-
rity of the RNA was checked by gel electrophoresis, and
concentration was determined spettrophotometrically.
Genome wide analysis of gene expression by microarray
Transcriptional difference: HOC-EC vs. HA-EC
We are aware that culture conditions alter gene expres-
sion. To this end, all the EC under investigation were ana-
lyzed under two different conditions: either seeded onto
type I collagen coated tissue culture plastic (BioCoat-Bec-
ton Dickinson, Bedford MA, USA) in endothelial cell
basal medium (EBM – Clonetics-BioWhittaker, Walkers-
ville MD, USA) plus 5% FBS or onto BioCoat plasticware
additionally coated with 1 μg/cm2 fibronectin (Plasma
Fibronectin, BD-Biosciences, Bedford MA, USA) in EBM
plus 5% FBS supplemented with and 10 ng/ml Epidermal
Growth Factor (EGF), 10 ng/ml Vascular Endothelial
Growth Factor (VEGF), 2 ng/ml Fibroblast Growth Factor
(FGF-2) (all from R&D System, Minneapolis MN, USA);
from here on respectively called "unexposed" or
"exposed" to a tumor/angiogenic environment.
To maximize the likelihood of detecting the intrinsic dif-
ferences between HOC-EC and HA-EC by minimizing the
influence of the artificial environment upon them, we
opted to select only those genes that were differentially
expressed regardless of the culture conditions.
Microarray analysis
GeneChip® Human Genome U95A Arrays (Affymetrix UK
Ltd, High Wycombe, UK) that monitor the expression of
approximately 12,000 genes were utilized to analyze the
transcriptional profiles of 3 independent HOC-EC
together with 2 HA-EC populations, under both
"exposed" and "unexposed" culture conditions. Raw
Affymetrix data were then processed for each of the 10
GeneChip® arrays.BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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Data analysis
For each probeset, the mean of the average difference val-
ues for the two "exposed" HA-EC samples was calculated
only if both were greater than 20 arbitrary units. Similarly,
the mean of at least two average difference values for the
three "exposed" HOC-EC samples was calculated only if
each of them was greater than 20 arbitrary units. The same
was done for the "unexposed" samples. Then, the log2 of
the HOC-EC versus HA-EC ratios was calculated only for
the probesets having both means available. Probesets
with log-ratios greater than 1.3 (corresponding to a fold
change of 2.5) for both "exposed" and "unexposed" sam-
ples were considered. Such a threshold was obtained by
fitting the distributions of the "exposed" and "unexposed"
log2-ratios with a normal distribution and calculating
upper bound of the 99% confidence interval.
Gene annotation
the probesets expressed to a greater extent in HOC-EC
than in HA-EC were divided into functional classes using
the publicly available Est Annotation and the Keyword
Clustering Machines [60] and were then manually
checked.
Typical endothelial genes: HOC-EC and HA-EC
Endothelial markers represented on the Affymetrix Gene-
Chip® were found by keyword search within the complete
probeset list annotated using the publicly available
SOURCE batch search [30,61]. The mean of average dif-
ference values for each transcript in HOC-EC and HA-EC
was calculated. Genes with the mean value greater than
500 were included in the list of expressed endothelial
markers shown in Table 2.
Additional information on gene expression was obtained
from the publicly available Reference database for gene
Expression Analysis (RefExA) of the Laboratory for System
Biology and Medicine (LSBM) (RCAST, University of
Tokyo) [25].
Quantitative real-time PCR
Two micrograms of total cellular RNA were reverse tran-
scribed (RT) using the Taqman Reverse Transcription Rea-
gents and Random Hexamer primers (Applied
Biosystems, Foster City, CA, USA) according to the manu-
facturer's protocols. To check for DNA contamination, a
control RT reaction was set up for each sample without the
addition of reverse transcriptase.
Quantitative real-time PCR was performed in 25 μl-reac-
tions on the GeneAmp 5700 Sequence Detection System
(Applied Biosystems) using either SYBR Green or TaqMan
chemistry. Primer sets for PCR amplifications are listed in
supplementary table 1 [see Additional file 1] and were
designed using the Primer Express 1.5 software (Applied
Biosystems) and synthesized by Gibco-Life Technologies.
Primer concentration was 200 nM for all SYBR Green
assays, except for 18s rRNA assay (50 nM); dissociation
curves were routinely performed. For transcripts analyzed
with TaqMan chemistry, specific Assay-on-Demands were
purchased from Applied Biosystems [see supplementary
table 1 in Additional file 1].
All assays were performed using duplicate samples of each
cDNA synthesis. Reverse transcription reactions and real-
time PCR analyses were carried out at least twice for each
gene transcript to determine consistency of results.
Gene expression of all transcripts was normalized to the
endogenous control gene human 18s rRNA and for each
population the ΔCt value was calculated (ΔCt = Cttargetgene
- Ct 18s). Statistical analysis with Student's t-test
(unpaired) on ΔCt values was performed to compare the
expression levels of target genes in EC samples from nor-
mal and neoplastic tissues.
Fold differences were calculated according to the compar-
ative ΔΔCt method (GeneAmp 5700 SDS User's Bulletin;
Applied Biosystems).
Northern Blot
For the analysis of tissue distribution, the MTE Array 2
(Clontech, Palo Alto CA, USA) was hybridized following
manufacturer's instructions. Briefly, the filter was pre-
hybridized for 30 min at 65°C with ExpressHyb (Clon-
tech). Hybridization was carried out O.N. at 65°C in
ExpressHyb containing 130 μg/ml fish sperm DNA, 6 μg/
ml Cot -1 DNA and the 32P-labeled cDNA probe. Filter
was washed with SSC2x/SDS0.1% at 65°C, followed by
washes at 55°C with SSC0.1x/SDS 0.5%. Because the
panel of human mRNAs loaded onto the MTE Arrays in
dot-blot format are normalized using eight different
housekeeping genes, the hybridization results can be
attributed to actual differences in target mRNA abun-
dance.
Densitometric analysis of the dots was performed with
Gel-Pro Analyzer Software (Media Cybernetics, Silver
Spring, MD). Optical Density (OD) values are reported in
Figure 3.
cDNA probe for ADAM23 corresponding to nt 2241–
2743 of GeneBank:NM_003812, and cDNA probe for
GPNMB corresponding to nt 416–984 of
GeneBank:NM_002510 were PCR amplified and gel puri-
fied.
In situ hybridization
In situ hybridization experiments were carried out with a
mixture of specific biotin-labeled oligonucleotide anti-BMC Genomics 2008, 9:201 http://www.biomedcentral.com/1471-2164/9/201
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sense (or sense) probes for ADAM23, GPNMB and PRSS3
(Metabion International AG, Martinsried, Germany)
listed in the supplementary Table 2 [see Additional file 1].
Human cancer specimens, such as adenocarcinoma brain
metastasis, angioma from a Von Hippel Lindau disease
patient, Ewing sarcoma, and medulloblastoma, were ana-
lyzed along with normal brain and Alzheimer's-diseased
brain.
After removal of paraffin, the tissue sections were rehy-
drated and heat-treated in 0.1 M sodium citrate (pH = 6),
washed for 5 min with water and then with 2× SSC, and
air dried. Sections were allowed to hybridize overnight at
room temperature in 15% formamide, 5× SSC, 10% dex-
tran sulphate, 1× Denhardt's solution (0.02% Ficoll400,
0.02% polyvinylpyrrolidone, 0.02% bovine serum albu-
min) and 400 μg/ml fish sperm DNA. Probe concentra-
tion was 10 nM for each oligonucleotide (corresponding
to 10 fmol/μl). Approximately 100 μl of hybridization
solution was applied to each slide.
After hybridization, sections were washed for 15 min in
2× SSC and for 10 min in water at room temperature. They
were rinsed three times in PBS/0.1% Triton, and incu-
bated for 20 min with blocking buffer (PBS/0.1% Triton,
5% FCS). Bound probes were detected using a mouse anti-
biotin antibody (DakoCytomation, Glostrup, Denmark).
Amplification of the signal was achieved with the
Vectastain elite ABC Kit (Vector Laboratories, Burlingame,
CA) according to the manufacturer's protocol. Colorimet-
ric detection was completed with the AEC Substrate kit
(Vector Laboratories). Finally, the tissue sections were
counterstained with hematoxylin and embedded on an
aqueous mounting medium.
Ethical consent
Endothelial cells have been isolated from biopsies col-
lected at the San Gerardo Hospital (Monza, Italy) from
patients undergoing therapeutic surgery from September
1998 to March 2004. The collection and use of the tissue
samples was approved by the Local Scientific Ethical
Committee in compliance with the principles enunciated
in the Helsinki Declaration [62]. Tissue samples (includ-
ing tumors) used for in situ hybridization were acquired
from the Oxford based Thomas Willis brain bank. The col-
lection of the tissues was done in accordance with the
requirements of the Human Tissue Act, with full informed
consent of participants and relatives. Ethical approval for
research to be conducted on the tissues was granted by
COREC (No: 1656).
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last growth factor-2 (basic); GPNMB: glycoprotein nmb;
HA-EC: human adrenal gland endothelial cells; HKC-EC:
human kidney carcinoma endothelial cells; HOC-EC:
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